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Question:   
An 80-year-old man with a medical history of Stage III chronic kidney disease, coronary artery 
disease, diabetes and stroke was prescribed a new medication for a low back sprain, and 
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Clinical Narrative: 
An 80-year-old man with history of Stage III chronic kidney disease, coronary artery 
disease, diabetes and stroke presented to the Emergency Department with new onset of 
behavioral changes and irregular jerking movements.  He had been recently prescribed baclofen 
10mg twice daily for a back strain suffered one week prior and was taking it as prescribed.  
Other prescribed medications included:  Aspirin 81mg daily, vitamin D3 2000 Units daily, 
clopidogrel bisulfate 75mg daily, insulin aspart, 8 Units with breakfast, 14 with lunch and 12 
with dinner, insulin glargine 35 Units daily, lisinopril 2.5mg daily, loratadine 10mg daily, 
magnesium 84mg daily, metoprolol 12.5mg twice daily, pravastatin sodium 20mg daily, 
prednisone 7.5mg daily, and sitagliptin phosphate 50 mg daily.   
Physical examination revealed continuous, involuntary flexion and extension 
movements of the upper and lower extremities, as well as repeated, involuntary turning of the 
head.  A serum baclofen concentration measured upon presentation was 0.16 mcg/mL (0.08-
0.40 mcg/mL).  The patient was admitted to the hospital, and his symptoms resolved within 48 
hours of admission and discontinuance of baclofen.  None of his routinely prescribed 
medications was changed or found to have known interactions with baclofen, and no other 
acute medical condition was revealed.  
 This unique case demonstrates an episode of acute dyskinesia secondary to oral 
baclofen toxicity.  Baclofen is a gamma-amino butyric acid (GABA) derivative that acts as an 
agonist at the GABAB receptor inducing presynaptic motor neuron inhibition and a central 
antispastic response [1].  While baclofen has been used primarily to limit spasticity in spinal 
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drug abuse [2].  Baclofen is: lipophilic, readily crosses the blood-brain barrier, has an 
elimination half-life of approximately two to six hours and primarily is cleared via renal 
excretion [1].  Clearance, therefore, will be decreased in patients with a reduced glomerular 
filtration rate (GFR).  Elderly patients may have seemingly normal creatinine, but with a marked 
reduction in GFR due to an overall lack of muscle mass and creatinine generation.  Moreover, 
this patient had known chronic kidney disease with a baseline creatinine between 1.4–1.6 
mg/dL and a GFR of 39–47 mL/min, placing him at increased risk for decreased drug clearance 
even at therapeutic levels of the drug.  
 This patient developed altered mental status and dyskinesia in the setting of therapeutic 
oral baclofen initiation, which is exceedingly rare, documented in only one other case report.  
Ryan, et al., reported the onset of dyskinesia in a 75-year-old man approximately four days 
after baclofen treatment was initiated.  The patient in that case report had a documented 
creatinine of 1.4 mg/dL; however, no reference range or GFR was reported.  Baclofen was 
implicated as the causative agent since the patient’s symptoms resolved after discontinuation 
of the drug and then reappeared with the re-institution of oral baclofen therapy (15mg daily) 
[3].  
 The exact mechanism of baclofen-induced dyskinesia is poorly understood.  Classically, 
drug-induced dyskinesia has been reported with the use of dopamine blocking agents (DBA).  It 
has been postulated that the relative dopaminergic hypofunction produced by DBAs causes 
overactivity of cholinergic mechanisms [3].  With respect to GABA receptors, rodent models 
have shown that GABAB receptors are expressed on both dopamine neurons, as well as GABA 
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inhibited both GABAergic and dopaminergic neurons, and decreased dopamine release [2].  
Furthermore, there have been reports of baclofen neurotoxicity in patients with pre-existing 
cerebral lesions, which may affect receptor activity and function [1].  Interestingly, our 
particular patient’s prescribed medications included zolpidem, which when used in conjunction 
with baclofen may increase sedation.  It has been suggested in the literature that concomitant 
use of central nervous system depressants may affect the concentration at which baclofen may 
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